$1.86
At close: May 1 EDT
$1.94
0.084.30%
Pre-Market: 7:28 AM EDT
Comments
Loading...
Compass Therapeutics Analyst Ratings and Price Targets | NASDAQ:CMPX | Benzinga
Compass Therapeutics Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024<. The low is $100 issued by Deutsche Bank on August 5, 2024. The 3 most-recent analyst ratings were released by New Street Research, Goldman Sachs, and Deutsche Bank on August 6, 2024, August 5, 2024, and August 5, 2024, respectively. With an average price target of $118.33 between New Street Research, Goldman Sachs, and Deutsche Bank, there's an implied 0.21% upside for Compass Therapeutics Corp from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
D. Boral Capital
HC Wainwright & Co.
Leerink Partners
Piper Sandler
Jefferies
1calculated from analyst ratings
Analyst Ratings for Compass Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/28/2025 | Buy Now | — | D. Boral Capital | Jason Kolbert45% | $32 → $32 | Maintains | Buy | Get Alert |
| 04/22/2025 | Buy Now | — | Guggenheim | Michael Schmidt56% | — | Reiterates | Buy → Buy | Get Alert |
| 04/21/2025 | Buy Now | — | HC Wainwright & Co. | Joseph Pantginis45% | $24 → $24 | Reiterates | Buy → Buy | Get Alert |
| 04/21/2025 | Buy Now | — | D. Boral Capital | Jason Kolbert45% | $32 → $32 | Maintains | Buy | Get Alert |
| 04/04/2025 | Buy Now | — | HC Wainwright & Co. | Joseph Pantginis45% | $10 → $24 | Maintains | Buy | Get Alert |
| 04/02/2025 | Buy Now | — | Guggenheim | Michael Schmidt56% | $12 → $12 | Reiterates | Buy → Buy | Get Alert |
| 04/02/2025 | Buy Now | — | Leerink Partners | Andrew Berens48% | $4 → $6 | Upgrade | Market Perform → Outperform | Get Alert |
| 04/01/2025 | Buy Now | — | D. Boral Capital | Jason Kolbert45% | $32 → $32 | Maintains | Buy | Get Alert |
| 02/27/2025 | Buy Now | — | D. Boral Capital | Jason Kolbert45% | $32 → $32 | Maintains | Buy | Get Alert |
| 02/25/2025 | Buy Now | — | D. Boral Capital | Jason Kolbert45% | $32 → $32 | Maintains | Buy | Get Alert |
| 02/24/2025 | Buy Now | — | Guggenheim | Michael Schmidt56% | → $12 | Initiates | → Buy | Get Alert |
| 02/19/2025 | Buy Now | — | Piper Sandler | Biren Amin41% | → $12 | Initiates | → Overweight | Get Alert |
| 02/10/2025 | Buy Now | — | Jefferies | Maury Raycroft32% | $7 → $8 | Maintains | Buy | Get Alert |
| 01/10/2025 | Buy Now | — | HC Wainwright & Co. | Joseph Pantginis45% | $10 → $10 | Reiterates | Buy → Buy | Get Alert |
| 01/08/2025 | Buy Now | — | HC Wainwright & Co. | Joseph Pantginis45% | $10 → $10 | Maintains | Buy | Get Alert |
| 01/08/2025 | Buy Now | — | D. Boral Capital | Jason Kolbert45% | $32 → $32 | Maintains | Buy | Get Alert |
| 12/23/2024 | Buy Now | — | D. Boral Capital | Jason Kolbert45% | → $32 | Initiates | → Buy | Get Alert |
| 11/15/2024 | Buy Now | — | HC Wainwright & Co. | Joseph Pantginis45% | $10 → $10 | Reiterates | Buy → Buy | Get Alert |
| 11/12/2024 | Buy Now | — | HC Wainwright & Co. | Joseph Pantginis45% | $10 → $10 | Reiterates | Buy → Buy | Get Alert |
| 11/11/2024 | Buy Now | — | HC Wainwright & Co. | Joseph Pantginis45% | $10 → $10 | Reiterates | Buy → Buy | Get Alert |
| 09/16/2024 | Buy Now | — | Ladenburg Thalmann | Aydin Huseynov34% | → $5 | Upgrade | Neutral → Buy | Get Alert |
| 08/12/2024 | Buy Now | — | HC Wainwright & Co. | Joseph Pantginis45% | $10 → $10 | Reiterates | Buy → Buy | Get Alert |
| 08/07/2024 | Buy Now | — | Wedbush | Robert Driscoll44% | $8 → $8 | Reiterates | Outperform → Outperform | Get Alert |
| 08/06/2024 | Buy Now | — | HC Wainwright & Co. | Joseph Pantginis45% | $10 → $10 | Reiterates | Buy → Buy | Get Alert |
| 06/03/2024 | Buy Now | — | HC Wainwright & Co. | Joseph Pantginis45% | $10 → $10 | Reiterates | Buy → Buy | Get Alert |
| 05/16/2024 | Buy Now | — | HC Wainwright & Co. | Joseph Pantginis45% | $10 → $10 | Reiterates | Buy → Buy | Get Alert |
| 05/14/2024 | Buy Now | — | HC Wainwright & Co. | Joseph Pantginis45% | $10 → $10 | Reiterates | Buy → Buy | Get Alert |
| 04/16/2024 | Buy Now | — | HC Wainwright & Co. | Joseph Pantginis45% | $10 → $10 | Reiterates | Buy → Buy | Get Alert |
| 03/22/2024 | Buy Now | — | Wedbush | Robert Driscoll44% | $8 → $8 | Reiterates | Outperform → Outperform | Get Alert |
| 03/21/2024 | Buy Now | — | HC Wainwright & Co. | Joseph Pantginis45% | $10 → $10 | Maintains | Buy | Get Alert |
| 08/03/2023 | Buy Now | — | HC Wainwright & Co. | Joseph Pantginis45% | → $10 | Reiterates | → Buy | Get Alert |
| 03/16/2023 | Buy Now | — | HC Wainwright & Co. | Joseph Pantginis45% | → $10 | Reiterates | → Buy | Get Alert |
| 01/31/2023 | Buy Now | — | Jefferies | Maury Raycroft32% | → $8 | Initiates | → Buy | Get Alert |
| 01/27/2023 | Buy Now | — | Stifel | Stephen Willey51% | → $9 | Initiates | → Buy | Get Alert |
| 12/16/2022 | Buy Now | — | EF Hutton | Michael King44% | → $10.3 | Initiates | → Buy | Get Alert |
| 11/10/2022 | Buy Now | — | Raymond James | Dane Leone46% | $5 → $8 | Maintains | Outperform | Get Alert |
| 11/03/2022 | Buy Now | — | HC Wainwright & Co. | Joseph Pantginis45% | $12 → $10 | Maintains | Buy | Get Alert |
| 05/23/2022 | Buy Now | — | HC Wainwright & Co. | Joseph Pantginis45% | → $12 | Assumes | → Buy | Get Alert |
| 05/05/2022 | Buy Now | — | SVB Leerink | Andrew Berens48% | $9 → $11 | Maintains | Outperform | Get Alert |
FAQ
What is the target price for Compass Therapeutics (CMPX) stock?
The latest price target for Compass Therapeutics (NASDAQ:CMPX) was reported by D. Boral Capital on April 28, 2025. The analyst firm set a price target for $32.00 expecting CMPX to rise to within 12 months (a possible 1549.48% upside). 27 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Compass Therapeutics (CMPX)?
The latest analyst rating for Compass Therapeutics (NASDAQ:CMPX) was provided by D. Boral Capital, and Compass Therapeutics maintained their buy rating.
When was the last upgrade for Compass Therapeutics (CMPX)?
The last upgrade for Compass Therapeutics Inc happened on April 2, 2025 when Leerink Partners raised their price target to $6. Leerink Partners previously had a market perform for Compass Therapeutics Inc.
When was the last downgrade for Compass Therapeutics (CMPX)?
There is no last downgrade for Compass Therapeutics.
When is the next analyst rating going to be posted or updated for Compass Therapeutics (CMPX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Compass Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Compass Therapeutics was filed on April 28, 2025 so you should expect the next rating to be made available sometime around April 28, 2026.
Is the Analyst Rating Compass Therapeutics (CMPX) correct?
While ratings are subjective and will change, the latest Compass Therapeutics (CMPX) rating was a maintained with a price target of $32.00 to $32.00. The current price Compass Therapeutics (CMPX) is trading at is $1.94, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
